MentalHealthDaily

Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for Rapid Treatment of Suicidal Depression (2023 Study)

by GLOOM

Major depressive disorder (MDD) is a critical public health issue, particularly due to the high risk of suicide associated with it. Traditional treatments often take weeks to show effects and sometimes increase suicide risk in the early phases of therapy. However, a new approach, the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), is showing promise in …

Gray Matter Abnormalities in Major Depression & Social Anxiety (2023 Analysis)

by GLOOM

Major depressive disorder (MDD) and social anxiety disorder (SAD) are two of the most prevalent mental health issues facing society today. They often occur together, challenging both patients and healthcare providers. Recent neuroimaging studies have begun to shed light on the unique and overlapping characteristics of these disorders, offering new insights into their complex neurobiology. …

Vortioxetine Efficacy for Major Depression & Comorbid Anxiety (2023 Study)

by GLOOM

The RELIEVE study provides pivotal insights into the effectiveness of vortioxetine in treating patients with Major Depressive Disorder (MDD) co-morbid with Generalized Anxiety Disorder (GAD). A subgroup analysis of the observational study highlights significant improvements in patient functioning, depression severity, cognitive symptoms, and quality of life. The findings underscore vortioxetine’s potential as a beneficial treatment …

NLRP3 Inflammasome & Depression: A Target for Antidepressant Development?

by GLOOM

The NLRP3 inflammasome stands at the crossroads of immune response and mental health, playing a pivotal role in the inflammatory processes implicated in depression. Researchers are exploring the intricate relationship between NLRP3 activation and depressive disorders, highlighting the potential for innovative treatments targeting this complex molecular pathway. Highlights: NLRP3 Inflammasome Activation: NLRP3, a component of …

Elevated Mitochondrial DNA (mtDNA) Levels Linked to Depression (Possible Diagnostic Biomarker)

by GLOOM

New research reveals that individuals with depression exhibit significantly higher levels of mitochondrial DNA (mtDNA) compared to healthy individuals. This suggests mtDNA could serve as a promising biomarker to improve depression diagnosis and treatment outcomes. Key facts: Meta-analysis of 12 studies with 1400 participants shows elevated mtDNA levels in blood and skin cells of depressed …

Dextromethorphan-Bupropion (Auvelity) for Depression: Clinical Trial Data for the New Rapid-Acting Antidepressant

by GLOOM

Major depressive disorder (MDD) is a significant global health concern, affecting over 280 million people worldwide. While numerous pharmacological options exist, challenges remain in achieving timely, robust, and sustained antidepressant response. Dextromethorphan-bupropion is a novel oral antidepressant recently approved by the FDA for MDD in adults that may address some of these unmet needs. Key …

Depression Linked to 12 Gastrointestinal Diseases in Genetic Analysis Study

by GLOOM

A new study published in Translational Psychiatry found evidence that genetic predisposition to depression is associated with increased risks of 12 different gastrointestinal diseases, including irritable bowel syndrome, non-alcoholic fatty liver disease, gastroesophageal reflux disease, ulcerative colitis, and more. The study helps establish a causal relationship between depression and gastrointestinal disease risk while minimizing confounding …